VTT searches for novel biomarkers and targets for preventing and treating type 2 diabetes
VTT is participating in two new European projects focusing on type 2 diabetes to identify therapeutic choices and strategies for preventing the disease.
The EU BetaBAT project aims at developing individual therapeutic choices for type 2 diabetics by identifying the connection between the genome and individual cell-level changes causing the disease.
The scientists will use systems biological tools to boost the capacity of beta cells and brown adipocytes for regaining homeostatic control.
The other EU project, DEXLIFE, aims at disease prevention by identifying novel diagnostic and predictive biomarkers to detect the progression toward type 2 diabetes in individuals at high risk of the disease.
Large-scale data will be acquired during the project, including information on genes and metabolites.
The intervention aimed at type 2 diabetes prevention will be set up in the real-life context of a major European health insurance system.
VTT's total budget in the two projects is 1.91 million Euros.
